Therapeutic CD200 mAb are being evaluated for cancers where blocking the inhibitory signal may enhance the homeostatic mechanisms and give increased phagocytosis of the cancer or enhance immune responses against the cancer [10], [39]. This evidence concerns the gene CD200 and cancer.